Details of Disease

General Information of Disease (ID: DISS6SNG)

• Disease Name: Malignant neoplasm
• Synonyms: malignant neoplasm; malignant childhood neoplasm; childhood neoplasm, malignant; paediatric cancer; pediatric cancer; malignant childhood tumor; malignant pediatric neoplasm; malignant childhood tumour; childhood cancer; malignant paediatric tumour; malignant paediatric neoplasm; malignant pediatric tumor; childhood malignant neoplasm
• Disease Class: 2A00-2F9Z: Solid tumour/cancer
• Definition: A malignant tumor that occurs in children. Representative examples include soft tissue and bone sarcomas (e.g. osteosarcoma) and embryonal neoplasms (e.g. hepatoblastoma and rhabdoid tumor).
• Disease Hierarchy:
  DIS3CD3W: Childhood neoplasm
  DISAT1Z9: Advanced cancer
  DISS6SNG: Malignant neoplasm
• ICD Code:
  ICD-11: ICD-11: 2A00-2F9Z
  ICD-10: ICD-10: C76-C80
  ICD-9: ICD-9: 140-239
  Expand ICD-11: '2D4Z
  Expand ICD-10: 'C76-C80; 'C76; 'C76.0; 'C76.1; 'C76.2; 'C76.3; 'C76.4; 'C76.5; 'C76.7; 'C76.8; 'C80; 'C80.0; 'C80.9
  Expand ICD-9: 140,141,142,143,144,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000
• Disease Identifiers:
  MONDO ID: MONDO_0006517
  UMLS CUI: C0278704
  MedGen ID: 82962

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
INCB039110	DMD9RV3	Phase 2	Small molecular drug	[1]
HER2-CAR T Cells	DMZXDBN	Phase 1	CAR T Cell Therapy	[2]
INO-3106	DMRO4CD	Phase 1	NA	[3]
SAR442257	DMXD5QP	Phase 1	Antibody	[4]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 10 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
RARG	TT1Q3IE	Limited	Genetic Variation	[5]
ALK	TTPMQSO	Strong	Genetic Variation	[6]
BRSK1	TTV6WMQ	Strong	Genetic Variation	[7]
CD6	TTMF6KC	Strong	Genetic Variation	[8]
CRYZ	TTP6UO8	Strong	Biomarker	[9]
GPR35	TT254XD	Strong	Biomarker	[10]
KMT5B	TTJGV7F	Strong	Genetic Variation	[11]
MRC1	TTKV8W5	Strong	Genetic Variation	[12]
MYCN	TT9JBY5	Strong	Altered Expression	[13]
TAGLN	TTDRZ9H	Strong	Genetic Variation	[11]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC28A3	DT4YL5R	Strong	Genetic Variation	[14]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CBR3	DEIVKZ8	Strong	Genetic Variation	[15]
UGT1A6	DESD26P	Strong	Genetic Variation	[14]

This Disease Is Related to 28 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BANF1	OTP7Z38L	Limited	Genetic Variation	[16]
MTFMT	OT1OIVJL	Limited	Biomarker	[17]
AMH	OT5FH4BD	Strong	Biomarker	[18]
ARID1B	OTILK3Q7	Strong	Genetic Variation	[19]
B4GALNT1	OTCY80HS	Strong	Altered Expression	[20]
BUB1B	OT8KME51	Strong	Genetic Variation	[21]
CCS	OTXHT3QO	Strong	Biomarker	[22]
CNTN3	OTC1274J	Strong	Genetic Variation	[21]
DGCR8	OT62LXE4	Strong	Genetic Variation	[23]
EXO1	OTI87RS5	Strong	Genetic Variation	[24]
GFI1B	OTRDW8YO	Strong	Biomarker	[25]
GLRA3	OTC8C2NC	Strong	Genetic Variation	[26]
GPC2	OT3WSQE1	Strong	Biomarker	[27]
KDM2B	OTDMCVW7	Strong	Biomarker	[28]
LMNB1	OT100T3P	Strong	Biomarker	[29]
LYPD4	OTYNO8BS	Strong	Biomarker	[30]
MCM8	OTC93H3S	Strong	Genetic Variation	[7]
MPI	OTBH6ZK1	Strong	Biomarker	[31]
PALB2	OT6DNDBG	Strong	Genetic Variation	[32]
PMS2	OTNLWTMI	Strong	Genetic Variation	[33]
PPIG	OTZ8BTTM	Strong	Biomarker	[34]
PTPRN2	OTL6SH28	Strong	Genetic Variation	[11]
RAD9A	OTJ3AJQU	Strong	Biomarker	[35]
RASSF4	OT7YLOFH	Strong	Biomarker	[36]
RB1	OT9VMY7B	Strong	Biomarker	[37]
SCARA3	OT46I38Y	Strong	Genetic Variation	[38]
SMARCB1	OT2LP7LJ	Strong	Biomarker	[39]
SNRPN	OTQB1ID1	Strong	Biomarker	[40]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8364).
• [2] ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT04401020) First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL. U.S. National Institutes of Health.
• [5] A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.
• [6] The ALK receptor in sympathetic neuron development and neuroblastoma.Cell Tissue Res. 2018 May;372(2):325-337. doi: 10.1007/s00441-017-2784-8. Epub 2018 Jan 27.
• [7] Genetic variation may modify ovarian reserve in female childhood cancer survivors.Hum Reprod. 2013 Apr;28(4):1069-76. doi: 10.1093/humrep/des472. Epub 2013 Jan 29.
• [8] Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice.Blood. 2011 Jul 28;118(4):1041-51. doi: 10.1182/blood-2011-02-338848. Epub 2011 May 31.
• [9] Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.Cancer. 2008 Jun 15;112(12):2789-95. doi: 10.1002/cncr.23534.
• [10] Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer.Pharmacogenet Genomics. 2017 Dec;27(12):445-453. doi: 10.1097/FPC.0000000000000309.
• [11] Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.J Natl Cancer Inst. 2017 Nov 1;109(11):djx058. doi: 10.1093/jnci/djx058.
• [12] An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome.Genet Med. 2019 Dec;21(12):2706-2712. doi: 10.1038/s41436-019-0577-z. Epub 2019 Jun 17.
• [13] Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma.Oncogene. 2019 Apr;38(15):2800-2813. doi: 10.1038/s41388-018-0611-7. Epub 2018 Dec 12.
• [14] Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30.
• [15] Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.J Clin Oncol. 2012 May 1;30(13):1415-21. doi: 10.1200/JCO.2011.34.8987. Epub 2011 Nov 28.
• [16] SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.Nat Genet. 2017 Nov;49(11):1613-1623. doi: 10.1038/ng.3958. Epub 2017 Sep 25.
• [17] Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients.EBioMedicine. 2019 Jun;44:730-740. doi: 10.1016/j.ebiom.2019.03.070. Epub 2019 Mar 30.
• [18] Early Detection of Ovarian Dysfunction by Anti-Mullerian Hormone in Adolescent and Young Adult-Aged Survivors of Childhood Cancer.J Adolesc Young Adult Oncol. 2019 Feb;8(1):18-25. doi: 10.1089/jayao.2018.0080. Epub 2018 Oct 3.
• [19] Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.Nat Genet. 2013 Jan;45(1):12-7. doi: 10.1038/ng.2493. Epub 2012 Dec 2.
• [20] GALNT9 gene expression is a prognostic marker in neuroblastoma patients.Clin Chem. 2013 Jan;59(1):225-33. doi: 10.1373/clinchem.2012.192328. Epub 2012 Nov 7.
• [21] Insufficiency of BUBR1, a mitotic spindle checkpoint regulator, causes impaired ciliogenesis in vertebrates.Hum Mol Genet. 2011 May 15;20(10):2058-70. doi: 10.1093/hmg/ddr090. Epub 2011 Mar 9.
• [22] Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study.J Am Heart Assoc. 2019 Jan 8;8(1):e009122. doi: 10.1161/JAHA.118.009122.
• [23] DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis.J Clin Invest. 2020 Mar 2;130(3):1479-1490. doi: 10.1172/JCI130206.
• [24] Influence of cancer-related gene polymorphisms on clinicopathological features in colorectal cancer.J Gastroenterol Hepatol. 2008 Jun;23(6):948-53. doi: 10.1111/j.1440-1746.2008.05307.x. Epub 2008 Jan 19.
• [25] Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma.Nature. 2014 Jul 24;511(7510):428-34. doi: 10.1038/nature13379. Epub 2014 Jun 22.
• [26] Genetic and clinical factors associated with obesity among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort.Cancer. 2015 Jul 1;121(13):2262-70. doi: 10.1002/cncr.29153. Epub 2015 May 11.
• [27] Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.Cancer Cell. 2017 Sep 11;32(3):295-309.e12. doi: 10.1016/j.ccell.2017.08.003.
• [28] Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.J Virol. 2019 Jun 14;93(13):e00273-19. doi: 10.1128/JVI.00273-19. Print 2019 Jul 1.
• [29] Membrane Proteome of Invasive Retinoblastoma: Differential Proteins and Biomarkers.Proteomics Clin Appl. 2018 Sep;12(5):e1700101. doi: 10.1002/prca.201700101. Epub 2018 Jun 13.
• [30] Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy.Environ Health. 2019 Aug 7;18(1):71. doi: 10.1186/s12940-019-0510-6.
• [31] Hepatic Hemangioma on SPECT Myocardial Perfusion Imaging.Clin Nucl Med. 2018 Jun;43(6):468-470. doi: 10.1097/RLU.0000000000002090.
• [32] Exploring the roles of PALB2 at the crossroads of DNA repair and cancer.Biochem J. 2014 Jun 15;460(3):331-42. doi: 10.1042/BJ20140208.
• [33] PMS2 inactivation by a complex rearrangement involving an HERV retroelement and the inverted 100-kb duplicon on 7p22.1.Eur J Hum Genet. 2016 Nov;24(11):1598-1604. doi: 10.1038/ejhg.2016.75. Epub 2016 Jun 22.
• [34] Enrollment on clinical trials does not improve survival for children with acute myeloid leukemia: A population-based study.Cancer. 2018 Oct 15;124(20):4098-4106. doi: 10.1002/cncr.31728. Epub 2018 Oct 6.
• [35] Reduced mRNA and protein expression of the genomic caretaker RAD9A in primary fibroblasts of individuals with childhood and independent second cancer.PLoS One. 2011;6(10):e25750. doi: 10.1371/journal.pone.0025750. Epub 2011 Oct 3.
• [36] RASSF4 is required for skeletal muscle differentiation.Cell Biol Int. 2020 Feb;44(2):381-390. doi: 10.1002/cbin.11238. Epub 2019 Sep 25.
• [37] Mesenchymal stromal cells having inactivated RB1 survive following low irradiation and accumulate damaged DNA: Hints for side effects following radiotherapy.Cell Cycle. 2017 Feb;16(3):251-258. doi: 10.1080/15384101.2016.1175798. Epub 2016 Apr 28.
• [38] Two-Dimensional Speckle Tracking Echocardiography-Derived Strain Measurements in Survivors of Childhood Cancer on Angiotensin Converting Enzyme Inhibition or Receptor Blockade.Pediatr Cardiol. 2018 Oct;39(7):1404-1412. doi: 10.1007/s00246-018-1910-z. Epub 2018 May 22.
• [39] SMARCB-1 deficient squamous cell carcinoma of a mediastinal cyst.Pathol Int. 2018 Oct;68(10):563-566. doi: 10.1111/pin.12720. Epub 2018 Sep 14.
• [40] Telomere Length-Associated Genetic Variants and the Risk of Thyroid Cancer in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS).Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):417-419. doi: 10.1158/1055-9965.EPI-18-0972. Epub 2018 Oct 30.